Xbrane Biopharma AB - ESG Rating & Company Profile powered by AI
If you are employed by Xbrane Biopharma AB and you wish to licence your ESG rating, please contact us. The dashboard contains a Q&A section about Xbrane Biopharma AB. This webpage displays a zero-cost ESG assessment covering Xbrane Biopharma AB.
Xbrane Biopharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 4.0, social score of 8.0 and governance score of 3.2.
5.1
Medium ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1725478325797)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
687 | Valbiotis SA | 5.2 | High |
687 | Zeria Pharmaceutical Co Ltd | 5.2 | High |
724 | Xbrane Biopharma AB | 5.1 | High |
724 | Catalyst Pharmaceuticals Inc | 5.1 | High |
724 | Adverum Biotechnologies Inc | 5.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1725478325797)
Frequently Asked Questions
Does Xbrane Biopharma AB have an accelerator or VC vehicle to help deliver innovation?
Does Xbrane Biopharma AB disclose current and historical energy intensity?
Does Xbrane Biopharma AB report the average age of the workforce?
Does Xbrane Biopharma AB reference operational or capital allocation in relation to climate change?
Does Xbrane Biopharma AB disclose its ethnicity pay gap?
Does Xbrane Biopharma AB disclose cybersecurity risks?
Does Xbrane Biopharma AB offer flexible work?
Does Xbrane Biopharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Xbrane Biopharma AB disclose the number of employees in R&D functions?
Does Xbrane Biopharma AB conduct supply chain audits?
Does Xbrane Biopharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Xbrane Biopharma AB conduct 360 degree staff reviews?
Does Xbrane Biopharma AB disclose the individual responsible for D&I?
Does Xbrane Biopharma AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Xbrane Biopharma AB disclose current and / or historical scope 2 emissions?
Does Xbrane Biopharma AB disclose water use targets?
Does Xbrane Biopharma AB have careers partnerships with academic institutions?
Did Xbrane Biopharma AB have a product recall in the last two years?
Does Xbrane Biopharma AB disclose incidents of discrimination?
Does Xbrane Biopharma AB allow for Work Councils/Collective Agreements to be formed?
Has Xbrane Biopharma AB issued a profit warning in the past 24 months?
Does Xbrane Biopharma AB disclose parental leave metrics?
Does Xbrane Biopharma AB disclose climate scenario or pathway analysis?
Does Xbrane Biopharma AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Xbrane Biopharma AB disclose the pay ratio of women to men?
Does Xbrane Biopharma AB support suppliers with sustainability related research and development?
Does Xbrane Biopharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Xbrane Biopharma AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Xbrane Biopharma AB involved in embryonic stem cell research?
Does Xbrane Biopharma AB disclose GHG and Air Emissions intensity?
Does Xbrane Biopharma AB disclose its waste policy?
Does Xbrane Biopharma AB report according to TCFD requirements?
Does Xbrane Biopharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Xbrane Biopharma AB disclose energy use targets?
Does Xbrane Biopharma AB disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Xbrane Biopharma AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Xbrane Biopharma AB
These potential risks are based on the size, segment and geographies of the company.
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.